AEEA-AEEA Linker

The core breakthrough of the third-generation ADC lies in its "stealth" design-ensuring the ADC remains undetected by the immune system, avoids hepatic clearance, and precisely reaches tumor tissues. The AEEA-AEEA linker serves as the key structural component enabling this concept.
The Chemical Basis of "Invisibility": The PEG (polyethylene glycol) segments in the AEEA-AEEA backbone exhibit high conformational flexibility and hydrophilicity. When the linker-payload is conjugated to the antibody surface, the PEG segments form a dynamic hydration layer around the antibody, resembling "whiskers." This hydration layer, approximately 2-3 nm thick, effectively shields hydrophobic regions and positive charge clusters on the antibody surface. Clearance receptors (e.g., SR-B1, MR) on immune cells (particularly macrophages and dendritic cells) primarily recognize hydrophobic and positively charged surfaces. The introduction of AEEA-AEEA adjusts the antibody surface zeta potential from +5 mV to near neutrality (-2 mV) while reducing the hydrophobic contact angle from 110° to 65°, significantly diminishing the recognition affinity of clearance receptors.
Extend the Circulatory Half-Life: Traditional ADCs (e.g., first-generation Mylotarg) have a half-life of only 2-3 days in the human body. Third-generation ADCs using the AEEA-AEEA linker (e.g., DS-8201 derivatives) can extend the half-life to 6-8 days in cynomolgus monkeys. The mechanism is as follows: The hydration layer reduces nonspecific binding with opsonins (e.g., C3 complement proteins, immunoglobulins), decreasing complement activation by approximately 70%; simultaneously, Fcγ receptor-mediated antibody-dependent cellular phagocytosis (ADCP) is significantly weakened. Pharmacokinetic parameters show a reduction in clearance (CL) from 15 mL/h/kg for traditional ADCs to 6-8 mL/h/kg, while the steady-state volume of distribution (Vss) remains at 0.15-0.2 L/kg (close to plasma volume), indicating that ADCs are primarily confined to the intravascular space and less prone to leakage into tissue spaces for degradation.
Clinical significance: A longer half-life allows for less frequent dosing (e.g., every 3 weeks instead of weekly), improving patient compliance. Meanwhile, the increased area under the blood concentration-time curve (AUC) enables more ADCs to accumulate in tumor tissue via the EPR effect (enhanced permeability and retention effect). Notably, the hydrophilicity of AEEA-AEEA does not affect the antibody's binding affinity to tumor antigens (KD value variation <1.5-fold), as the linker conjugation sites are typically chosen on the Fc region or lysine/cysteine residues away from the CDR region. This "invisible yet active" design is precisely why the AEEA-AEEA linker is highly favored in third-generation ADCs.